Bloomberg News

German Review Panel Sees Added Benefit for J&J Hepatitis C Drug

January 16, 2012

Jan. 16 (Bloomberg) -- Germany’s IQWiG drug-review panel found that Johnson & Johnson’s hepatitis C treatment telaprevir showed evidence of an added benefit when used together with older treatments, according to a statement posted on the panel’s website today.

Germany’s Federal Joint Committee will use IQWiG’s recommendation to make a final ruling on whether telaprevir, also known by the brand name Incivo, helps patients more than existing therapies do, a key factor in setting the price of new drugs in the German system.

To contact the editor responsible for this story: Naomi Kresge at nkresge@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus